We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Family Medicine & Nutrition

Exploring the Gut Microbiota-Insomnia Connection: Evidence and Controversies

MedXY Editorial Team•Oct 3, 2025•Family Medicine & Nutrition
gut microbiotaInsomniaMendelian Randomizationmicrobiome

Highlight

– Specific gut bacterial taxa may causally contribute to the risk of insomnia.
– Insomnia itself may alter the abundance of certain gut bacteria, indicating a bidirectional relationship.
– Mendelian randomization analysis identified 41 bacterial groups linked to insomnia risk with some showing stronger causal evidence.
– Experts advise caution in attributing causality due to potential confounding and population limitations.

Study Background and Disease Burden

Insomnia is a prevalent sleep disorder characterized by difficulties initiating or maintaining sleep, affecting quality of life and increasing risk for psychiatric and metabolic diseases. Recent research has increasingly acknowledged the gut-brain axis as a potential modulator of neurological and psychiatric conditions, including sleep disorders. The gut microbiome—the collective community of microorganisms in the gastrointestinal tract—has emerged as an influential factor in neurobehavioral health. However, establishing a causal relationship between specific gut bacteria and insomnia has remained challenging due to confounding factors and bidirectional influences.

Study Design

To investigate potential causal links between gut microbiota composition and insomnia, researchers led by Shangyun Shi at Nanjing Medical University employed a two-sample Mendelian randomization (MR) approach. MR uses genetic variants as instrumental variables to infer causality, thereby minimizing confounding and reverse causation biases.

The study utilized genome-wide association study (GWAS) summary statistics of insomnia from 386,533 individuals and integrated gut microbiome data from two large cohorts: 18,340 participants from the MiBioGen Alliance and 8,208 from the Dutch Microbiome Project. MR was applied bidirectionally to assess whether genetically predicted gut microbiota abundance influences insomnia risk and whether genetic predisposition to insomnia affects gut microbiota composition.

Key Findings

The MR analysis identified 14 bacterial groups potentially increasing insomnia risk, exhibiting odds ratios (OR) ranging from 1.01 to 1.04, and eight bacterial groups associated with a decreased risk (ORs 0.97–0.99).

Data from the Dutch cohort corroborated these findings with similar OR estimates, but after adjustments for multiple testing using false discovery rate (FDR) correction, only the association with Clostridium innocuum remained statistically significant (FDR = 0.007).

Reverse MR analyses revealed that insomnia genetically influences gut microbiota, with increases of up to 4.43-fold in the abundance of 12 bacterial taxa and decreases between 43% and 79% in seven other taxa. Notably, a bidirectional causal relationship was observed between Odoribacter species and insomnia within the Dutch dataset.

The authors conducted sensitivity analyses to test for pleiotropy (where genetic variants affect multiple traits) and reported none, reinforcing the robustness of inferred causal links. The study identified a total of 41 gut bacterial taxa with potential causal associations with insomnia.

Expert Commentary

While this study represents an advance by leveraging MR methodology to dissect complex microbiota-insomnia associations, external experts remain cautious in interpreting these associations as definitively causal. The modest odds ratios for many bacterial groups denote small effect sizes. Moreover, participants were primarily of European descent, limiting extrapolation to diverse populations with differing microbiota profiles.

Environmental and lifestyle factors such as diet, stress, and medications—known influencers of both insomnia and gut microbiome—were not accounted for by the genetic analysis, constraining causal inference. Experts also note that MR assumptions, while mitigating some biases, cannot completely exclude horizontal pleiotropy or unmeasured confounding.

Mechanistically, gut bacteria may impact insomnia through modulation of host neurotransmitters, immune signaling, or metabolite production, though direct functional studies are needed to elucidate pathways. The bidirectional relationship observed emphasizes the complexity of gut-brain interactions in sleep regulation.

Conclusion

This study provides preliminary evidence supporting a bidirectional causal association between specific gut microbiota taxa and insomnia risk. It highlights Clostridium innocuum and Odoribacter species as key bacterial groups warranting further mechanistic and interventional research.

However, clinical translation requires cautious interpretation given the study’s population and methodological limitations. Future research integrating environmental factors, longitudinal study designs, and functional microbiome analyses could clarify causal pathways and enable microbiome-targeted therapeutic strategies for insomnia.

References

Yang J, Su T, Zhang Y, Jia M, Yin X, Lang Y, Cui L. A bidirectional Mendelian randomization study investigating the causal role between gut microbiota and insomnia. Front Neurol. 2023 Dec 7;14:1277996. doi: 10.3389/fneur.2023.1277996 . PMID: 38145126 ; PMCID: PMC10740168 .

  • PDF (2.9 MB)

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Decoding Pseudomonas aeruginosa Subtypes: Implications for Clinical Variability in BronchiectasisDistinct Pseudomonas aeruginosa abundance and interaction patterns in bronchiectasis patients reveal heterogeneity influencing clinical outcomes and treatment responses, offering new avenues for personalized management.Sep 18, 2026Intestinal Serotonergic Vagal Signaling: A Novel Link Between Gut Microbiota and Hypertension ManagementRecent research identifies intestinal serotonin 5-HT3a receptor signaling via vagal neurons as a key mediator of microbiota-induced hypertension, offering new insights into resistant hypertension and potential therapeutic targets.Sep 17, 2026Metabolic Signatures and Causal Markers in MRI-Confirmed Lacunar Stroke: Insights from Observational and Mendelian Randomization AnalysesThis study identifies glycine and specific lipid cholesterol proportions as metabolomic markers causally linked to lacunar stroke subtypes, enhancing understanding of cerebral small vessel disease pathogenesis and potential biomarkers.Sep 15, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
The Microbiome in Critical Illness: Transforming ICU Care Through Microbial Insights
This review explores how the human microbiome influences management and outcomes in critically ill patients, emphasizing gastrointestinal microbial dynamics, disruption by critical illness and therapies, and emerging interventions to restor
Aug 28, 2026
Gut Microbiota and Metabolomic Signatures as Predictors of Immunotherapy Outcomes in MASLD and Viral HCCDistinct gut microbial profiles but shared metabolomic markers, especially fecal acetate, predict response and survival with combination immunotherapy in metabolic dysfunction-associated and viral hepatitis-related hepatocellular carcinoma.Aug 22, 2026
Gut Microbiota-Derived Imidazole Propionate as a Predictor of Cardiometabolic Risk in Coronary Artery Disease: Evidence and Clinical ImplicationsEmerging evidence identifies circulating imidazole propionate, a gut microbiota-derived metabolite, as an independent predictor of major adverse cardiovascular events in patients with coronary artery disease, offering novel insights into peAug 18, 2026